home > epc > autumn 2002 > clinical trials in bulgaria
European Pharmaceutical Contractor

Clinical Trials in Bulgaria

Site Selection and Investigator Identification

Highly critical to the success of any study, these two issues require the utmost care. The decision-making process regarding both site and investigator should make full use of all local expertise:
Local opinion leaders will be well acquainted with the available professionals in the
area, as well as with its hospital structure and facilities
Local CROs and pharmaceutical companies' affiliate offices (affiliates) will have
hands-on experience of potential investigators and sites

This expertise should provide valuable information regarding site potential and suitability for trial requirements, for example available beds, medical/lab equipment, clinical supply, storage facilities and so on. They can also be helpful for assessing a site's desirability, for instance location, physical layout, access to IRB/IEC, quality of clinical trial teams and a suitable patient pool. Utilising these resources, whilst fundamental, is not without potential problems.

For example one should always be aware of the risk of commercial interests affecting advice given by affiliates during site/investigator selection. In an emerging scientific market commercial potential is limited, and therefore sales and marketing opportunities should be carefully balanced with clinical development. In our opinion, the emphasis should be put on clinical development performance. It is much more important to assess a site's real suitability and an investigator's capabilities in new drug trial implementation, rather than future marketing potential.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

In our Summer 2002 issue, Dr Milen Vrabevski, Medical Director at Comac Medical, began an in-depth overview of clinical trials in his native Bulgaria. Here he continues his investigation of the advantages and potential pitfalls for multinational pharmaceuticals operating in emerging scientific markets.

Dr Milen Vrabevski is Medical Director of Comac Medical Ltd., a full service small CRO based in Sofia, Bulgaria. He has over five years of experience in the pharmaceutical industry, mainly in the field of clinical research.

After graduating from the Medical University of Varna in 1995, Milen began his career working as a Junior Doctor in a surgery department, and then as a Medical Representative of a pharmaceutical company before founding Comac Medical Ltd. in 1997, assuming the position of Director.

Being one of the pioneers in the GCP and Quality of Life (QoL) area in his country, Milen has participated in conducting all company clinical studies and QoL projects.

Dr Milen Vrabevski
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

Industry Events



SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement